Table 1 Baseline characteristics for all treated participants PK, pharmacokinetics.

From: Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants

Characteristica

Placebo (n = 6)b

Milvexian 50 mgc (n = 6)

Milvexian 200 mg (a)c,d (n = 8)

Milvexian 200 mgc (n = 6)

Milvexian 500 mge (n = 6)

Total (N = 32)

Male gender, n (%)

6 (100.0)

6 (100.0)

8 (100.0)

6 (100.0)

5 (83.3)

31 (96.9)

Age

41.0 (23–48)

35.5 (29–49)

37.0 (29–54)

29.5 (23–40)

39.0 (30–55)

36.5 (23–55)

Japanese race, n (%)

6 (100.0)

6 (100.0)

8 (100.0)

6 (100.0)

6 (100.0)

32 (100.0)

Body mass index, kg/m2

20.50 (19.5–23.3)

22.90 (19.6–24.2)

–

23.20 (19.3–24.3)

22.90 (21.6–23.7)

22.55 (19.3–24.3)

  1. aAll values presented as median (minimum–maximum) unless otherwise stated.
  2. bOne participant in Cohort 3 (milvexian 500 mg or placebo) assigned to placebo was discontinued early due to participation in multiple clinical trials; this participant was excluded from analysis and replaced.
  3. cMilvexian 50 mg and 200 mg were administered under fasted conditions.
  4. dCohort 2a, milvexian 200 mg (a), includes unblinded and early terminated participants from Cohort 2 (milvexian and placebo participants). These participants were excluded from the evaluable PK population.
  5. eMilvexian 500 mg was administered under fed conditions.
Back to article page